Barclays
OKUR

Barclays’s OnKure Therapeutics OKUR Stock Holding History

Barclays’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Sell
25,000
-2,242
-8% -$6.92K ﹤0.01% 4008
2025
Q4 		$79K Buy
27,242
+26,621
+4,287% +$79.7K ﹤0.01% 4643
2025
Q3 		$1.71K Sell
621
-375
-38% -$929 ﹤0.01% 5154
2025
Q2 		$2.38K Sell
996
-5,769
-85% -$15.1K ﹤0.01% 5027
2025
Q1 		$29.1K Sell
6,765
-1,976
-23% -$11.1K ﹤0.01% 4729
2024
Q4 		$75.2K Buy
8,741
+8,718
+37,904% +$132K ﹤0.01% 4655
2024
Q3 		$389 Buy
23
+18
+360% +$266 ﹤0.01% 5155
2024
Q2 		$70 Sell
5
-811
-99% -$13.7K ﹤0.01% 4763
2024
Q1 		$13.5K Sell
816
-1,628
-67% -$26.9K ﹤0.01% 4786
2023
Q4 		$39.1K Sell
2,444
-5,368
-69% -$335K ﹤0.01% 4810
2023
Q3 		$595K Buy
7,812
+425
+6% +$28.9K ﹤0.01% 2684
2023
Q2 		$485K Buy
7,387
+194
+3% +$15.6K ﹤0.01% 2773
2023
Q1 		$430K Hold
7,193
– – ﹤0.01% 3370
2022
Q4 		$168K Hold
7,193
– – ﹤0.01% 3945
2022
Q3 		$241K Buy
7,193
+1,798
+33% +$59K ﹤0.01% 3100
2022
Q2 		$143K Buy
5,395
+5,039
+1,415% +$117K ﹤0.01% 3602
2022
Q1 		$10K Buy
+356
New +$19.9K ﹤0.01% 4606

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Barclays's OKUR Position: Q1 2026 in Review

Barclays reduced its OnKure Therapeutics (OKUR) stake by 8.2% in Q1 2026, selling an estimated $6.92K and leaving 25,000 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #4008.

Barclays first reported a position in OKUR in Q1 2022 and has held it in 17 quarters since. The position peaked at $595K in Q3 2023. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Barclays held 25,000 shares of OnKure Therapeutics worth $104K as of Q1 2026.
  • Barclays sold 2,242 OnKure Therapeutics shares in Q1 2026, an estimated $6.92K.
  • OnKure Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4008 holding.
  • Barclays first reported a position in OnKure Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's OnKure Therapeutics position peaked at $595K in Q3 2023.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.